Welcome, Guest
Username: Password: Remember me
Off Topic on Adult (=regenerative) cell technology, but very much related i.e. pills and drugs of which we do not know if they work
  • Page:
  • 1

TOPIC: ARNA

ARNA 19 Mar 2018 16:52 #11553

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2859
  • Thank you received: 204
Interesting results from non stem cell product in UC.
Nice peek at what real stat sig results look like causing big stir AH.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC). Patients receiving the 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints.

Relative to placebo, there was a statistically significant (p = 0.009) 0.99 point improvement in a 3-component (stool frequency, rectal bleeding and findings on endoscopy) Mayo Clinic Score (ranging from 0 to 9) with etrasimod 2 mg at week 12. In the 1 mg group, there was a 0.43 point improvement in 3-component Mayo Clinic Score at week 12 relative to placebo, which was not statistically significant (p = 0.146). Significantly more patients in the etrasimod 2 mg group achieved endoscopic improvement compared with placebo (41.8% vs. 17.8%, p = 0.003).
The proportion of patients achieving clinical remission, defined by the 3-component Mayo Clinic Score, was 33.0% in the etrasimod 2 mg group compared to 8.1% for the placebo group (p < 0.001). Remission as defined by the 4-component Total Mayo Clinic Score was 24.5% and 6.0% for etrasimod 2 mg and placebo, respectively (p = 0.004).

Please Log in or Create an account to join the conversation.

ARNA 19 Mar 2018 17:25 #11554

  • rodney.strongg
  • rodney.strongg's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1361
  • Thank you received: 19

myownhedgefund wrote: Interesting results from non stem cell product in UC.
Nice peek at what real stat sig results look like causing big stir AH.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC). Patients receiving the 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints.

Relative to placebo, there was a statistically significant (p = 0.009) 0.99 point improvement in a 3-component (stool frequency, rectal bleeding and findings on endoscopy) Mayo Clinic Score (ranging from 0 to 9) with etrasimod 2 mg at week 12. In the 1 mg group, there was a 0.43 point improvement in 3-component Mayo Clinic Score at week 12 relative to placebo, which was not statistically significant (p = 0.146). Significantly more patients in the etrasimod 2 mg group achieved endoscopic improvement compared with placebo (41.8% vs. 17.8%, p = 0.003).
The proportion of patients achieving clinical remission, defined by the 3-component Mayo Clinic Score, was 33.0% in the etrasimod 2 mg group compared to 8.1% for the placebo group (p < 0.001). Remission as defined by the 4-component Total Mayo Clinic Score was 24.5% and 6.0% for etrasimod 2 mg and placebo, respectively (p = 0.004).


HF, seriously, at this point who on this site could possibly care about that post - why don't you try to come up with something positive that could cheer up Fas.

Please Log in or Create an account to join the conversation.

ARNA 19 Mar 2018 17:46 #11555

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2859
  • Thank you received: 204
You wrote almost the exact same post on the Llyod Dean issues but Fas himself came back to say he was interested.
To know what else is progressing on GI issues which have been discussed here is a good thing.
Besides...these type of pops rarely last and may represent opportunity for those who understand are a bit more sophisticated. You may not understand and I have no interest in explaining.

Please Log in or Create an account to join the conversation.

ARNA 19 Mar 2018 19:33 #11556

  • rodney.strongg
  • rodney.strongg's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1361
  • Thank you received: 19

myownhedgefund wrote: You wrote almost the exact same post on the Llyod Dean issues but Fas himself came back to say he was interested.
To know what else is progressing on GI issues which have been discussed here is a good thing.
Besides...these type of pops rarely last and may represent opportunity for those who understand are a bit more sophisticated. You may not understand and I have no interest in explaining.

/

Good, I have no interest in your "explaining":bash:

Please Log in or Create an account to join the conversation.

ARNA 06 Apr 2018 14:16 #11643

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2859
  • Thank you received: 204
Smart CEO/CFO at ARNA recently raised funds at $41+
Now over 400 million in the coffers.
You see Cytori...you raise when the PPS rises...something that admittedly hasn't happened in quite some time here but there were times this company could have risen much larger $ funds that would have put them in a better position and for a longer period than the usual biannual secondaries necessary here for more than 12 years !!!!
Recent Good phase 2 results and a much lower PPS may make ARNA worth a look soon for those with some risk capital.
More DD work needed though.

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.218 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites